多巴胺D3受体基因多态性与精神分裂症患者迟发性运动障碍的关联分析

目的　观察广州地区汉族伴或不伴迟发性运动障碍 (TD)的精神分裂症患者多巴胺D3受体 (DRD3)基因Ser 9 Gly多态性分布 ,探讨DRD3基因Ser 9 Gly多态性与TD发生的关系。方法对 1 4 0例精神分裂症患者采用不自主运动评定量表 (AIMS)进行评定 ,其中 53例伴TD ,87例不伴TD。应用聚合酶链反应和限制性内切酶长度多态性方法 ,检测 1 4 0例患者的DRD3基因Ser 9 Gly多态性 ,并对DRD3各等位基因及基因型与精神分裂症患者的TD表型进行关联分析。结果　 (1 )TD组与无TD组患者基因型总体分布的差异无显著性 (χ2 =5 6 ,υ =2 ,P >0 0 5) ,等位基因频数分布的差异有显著性 (χ2 =5 1 1 ,υ =1 ,P <0 0 5)。 (2 )按性别分组后 ,在男性患者中 ,伴TD患者较不伴TD患者 1 / 1基因型和等位基因 1频率的差异有显著性 (χ2 =5 2 4 ,χ2 =5 0 6 ,P <0 0 5) ,等位基因 2的差异有显著性 (χ2 =5 0 6 ,P <0 0 5)。在女性患者中 ,DRD3各基因型及等位基因的频率的差异均无显著性 (P >0 0 5)。结论　DRD3基因Ser 9 Gly多态性可能与精神分裂症尤其是男性患者的TD关联     

多巴胺D2受体基因与迟发性运动障碍关联研究

目的探讨DRD2基因TaqI多态性的分布与迟发性运动障碍(TD)的关联性.方法应用聚合酶链反应-限制性片段长度多态的方法,检测100例精神分裂症伴TD患者、60例无TD患者和102名正常人DRD2基因TaqI多态性,比较各组等位基因和基因型频率分布的差异.结果经吻合度检验,精神分裂症伴有TD组、无TD组和正常对照组DRD2基因各基因型的分布均符合Hardy-Weinberg平衡法则(x2=0.242,0.208,0.002,υ均=1,P均＞0.05);经比较,显示各基因型及等位基因在各组间分布无显著性差异(经Z检验,υ均=1,P均＞0.05);TD患者DRD2基因多态分布在不同性别之间无显著性差异(P＞0.05);在TD组中,基因型频数及等位基因频数与病程、服药时间、药物、剂量和AIM评分无显著性意义(P＞0.05).结论DRD2基因TaqI多态性可能与TD的发生无关联性.     

5-羟色胺2A受体基因多态性与精神分裂症患者迟发性运动障碍的关联分析

目的　探讨5- 羟色胺2A( 5- HT2A)受体基因A 1 4 38G、T1 0 2C多态性与精神分裂症伴迟发性运动障碍(TD)的相关性。方法　先用异常不自主运动量表(AIMS)评定精神分裂症男性患者有无TD及其严重程度,有4 2例符合TD(AIMS总分≥3分)者和51例与TD组严格相匹配的非TD者入组,采用简明精神病评定量表(BPRS)评定精神症状,应用聚合酶链反应 限制性片段长度多态性方法分析5 HT2A受体基因的A 1 4 38G、T1 0 2C多态性位点的多态性。结果　①5- HT2A受体基因A 1 4 38G和T1 0 2C两位点多态性呈完全连锁不平衡,TD组与非TD组的两多态性位点的基因型总体分布无显著性差异( χ2 =4 37,v =2 ,P >0 . 0 5) ,在TD组有更高的C/A等位基因频率,与非TD组有显著性差异( χ2 =4 . 36 ,v =1 ,P <0. 0 5)。②不同基因型间的人口学和临床学资料(如:病程、服药总时间、日服抗精神病药物剂量、AIMS和BPRS的评分)间无显著性差异(P >0. 0 5)。结论　5 -HT2A受体基因的A 1 4 38G、T1 0 2C多态性可能与男性精神分裂症患者的TD相关联。     

5-羟色胺2A受体基因多态性与精神分裂症患者迟发性运动障碍的关联分析

目的　探讨 5 羟色胺 2A(5 HT2A)受体基因A14 38G多态性与精神分裂症伴迟发性运动障碍 (TD)的相关性。方法　先用异常不自主运动量表 (AIMS)评定精神分裂症男性患者有无TD及其严重程度 ,再对 4 2例符合TD(AIMS总分≥ 3分 )者和与TD组严格相匹配的 5 1例非TD者 ,采用简明精神病评定量表 (BPRS)评定精神症状 ,应用聚合酶链反应 限制性片段长度多态性方法分析 5 HT2A受体基因的分布频率。结果　 (1)经吻合度检验 ,TD组、非TD组的 5 HT2A受体基因A14 38G多态性位点的基因型分布均符合Hardy Weinberg平衡法则 (χ2 值分别为 0 0 6、0 0 2 ,υ均 =1,P均 >0 0 5。 (2 )TD组与非TD组的基因型总体分布的差异无显著性 (χ2 =4 37,υ =2 ,P >0 0 5 ) ,等位基因频率分布的差异有显著性 (χ2 =4 36 ,υ=1,P <0 0 5 )。 (3)TD组的AIMS和BPRS的评分分别为 (6 5± 1 8)分和 (5 1 2± 7 8)分 ,非TD组分别为 0分和 (5 0 3± 7 4 )分 ,差异无显著性 (P >0 0 5 )。结论　 5 HT2A受体基因的A14 38G多态性可能与男性精神分裂症患者的TD相关联。     

多巴胺D4受体基因与氯氮平临床疗效个体差异的关系

目的　探讨多巴胺D4受体基因第 3外显子 4 8bp可变重复序列多态性与氯氮平临床疗效个体差异的关系。方法　 81例精神分裂症患者单一服氯氮平治疗 6～ 8周 ,利用阳性与阴性症状量表 (PANSS)评定氯氮平的疗效。采用聚合酶链式反应 (PCR)、变性聚丙烯酰胺凝胶电泳结合银染技术 ,检测精神分裂症患者的基因型和等位基因频率。同时为排除氯氮平个体代谢能力的遗传差异带来的混淆 ,检测了每个患者的血清氯氮平浓度。结果　DRD4基因第 3外显子 4 8bp可变重复序列多态性的 5等位基因的纯合子基因型 (DRD4 5 / 5 )和 5等位基因 (DRD4 5 )的频率在氯氮平有效组和无效组之间有显著性差异。氯氮平治疗精神分裂症阳性症状、阴性症状的有效组和无效组间基因型及等位基因的频率相比无显著性差异。结论　氯氮平治疗精神分裂症的总疗效个体差异与DRD4基因第 3外显子 4 8bp可变重复序列相关 ,携带DRD4 5等位基因者和DRD4 5 / 5基因型者疗效好     

多巴胺D2受体基因rs1800497多态性与精神分裂症的关联分析

目的 探讨中国汉族人群多巴胺D2受体（DRD2）基因rs1800497多态性与精神分裂症发病的关系及其与性别的关联性.方法 采用TaqMan法检测200例精神分裂症患者（患者组）和219名健康对照（对照组）DRD2基因rs1800497单核苷酸多态性（SNP）,并对等位基因、基因型频率进行比较.结果 患者组与对照组rs1800497等位基因分布和基因型分布差异均无统计学意义（P＞0.05）.患者组或对照组不同性别rs1800497等位基因分布和基因型分布差异均无统计学意义（P＞0.05）.男性患者组与对照组相比或女性患者组与对照组相比,rs1800497等位基因分布和基因型分布差异均无统计学意义（P＞0.05）.结论 中国汉族人群DRD2 rs1800497位点可能不是精神分裂症的易感位点.     

5-羟色胺2C受体基因启动子区多态性与迟发性运动障碍的关联分析

目的　探讨 5 羟色胺 2C(5 HT2C)受体基因启动区 - 759C/T和 - 697G/C单碱基置换多态性与精神分裂症伴迟发性运动障碍 (TD)的相关性。方法　先用异常不自主运动量表 (AIMS)评定精神分裂症男性患者有无TD及其严重程度 ,再对 42例符合TD(AIMS总分≥ 3分 )者和与TD组严格相匹配的 50例非TD者 ,采用简明精神病评定量表 (BPRS)评定精神症状 ,并应用聚合酶链反应 限制性片段长度多态性方法分析 5 HT2C受体基因的分布频率。结果　 (1 )TD组的 - 697C(突变型 )半合子型频率 (38% )高于非TD组 (1 8% ;χ2 =4 7,P =0 0 3 ,OR =2 8)。TD组 - 759T(突变型 )半合子型频率和 - 759T/ - 697C突变型单倍体频率虽高于非TD组 ,但差异均无显著性 (χ2 值分别为 2 9和 4 9,P =0 0 9)。 (2 )TD组的AIMS和BPRS评分分别为 (6 5± 1 8)分和 (51 2± 7 8)分 ,非TD组分别为 0分和(50 0± 7 3)分 ,差异无显著性 (P >0 0 5)。结论　 5 HT2C受体基因启动控制区的 - 697G/T单碱基置换突变可能是精神分裂症患者发生TD的易感因素之一     

细胞色素P4502D6及多巴胺D2受体基因多态性与利培酮疗效的关联

目的 探讨细胞色素P450 2D6(cytochromes P450 2D6,CYP2D6)基因多态性、多巴胺D2受体(dopamine D2 receptor,DRD2)基因多态性与利培酮疗效的相关性.方法 对199例首发精神分裂症患者给予利培酮治疗8周,治疗前后采用阳性和阴性症状量表(Positive and Negative Syndrome Scale,PANSS)评定疗效,同时收集198例正常对照进行病例-对照分析.采用聚合酶链反应序列特异性引物扩增技术检测CYP2D6/C188T、DRD2 TaqIA基因型,分析二者与利培酮临床效应的相关性.结果 病例组和对照组CYP2D6/C 188T的基因型和等位基因频率相比,差异有统计学意义(CC:40.7％ vs.21.2％,CT:25.6％ vs.45.5％,TT:33.7％vs.33.3％,P＜0.05;C:53.5％ vs.43.9％,T:46.5％ vs.56.1％,P＜0.05),病例组和对照组DRD2 TaqIA的基因型和等位基因频率相比,差异有统计学意义(A1A1:29.1％ vs.35.9％,A1A2:37.7％ vs.47.5％,A2A2:33.2％ vs.16.6％,P＜0.05; A1:48.0％ vs.59.6％,A2:52.0％ vs.40.4％,P＜0.05);CYP2D6/C 188T与DRD2TaqIA的交互作用对PANSS减分率的影响没有统计学意义(F=0.735,P＞0.05);CYP2D6/C188T,DRD2TaqIA与性别的交互作用对PANSS减分率的影响具有统计学意义(F=3.214,P＜0.05).结论 CYP2D6基因C188T多态性和DRD2基因TaqIA多态性不是影响精神分裂症患者利培酮临床疗效的易感因素,但是在协变量性别的作用下,上述基因多态性的交互作用可能影响利培酮的疗效.     

多巴胺D5受体基因多态性与精神分裂症的关联研究

目的　探讨昆明地区汉族人群多巴胺D5受体 (DRD5 )基因多态性与精神分裂症的关系。方法　对 79例精神分裂症患者 (患者组 )和 75名正常对照者 (对照组 )采用聚合酶链反应 (PCR)扩增DRD5基因二核苷酸多态性片段 ,并通过聚丙烯酰胺凝胶电泳对PCR扩增产物进行多态性分型鉴定。比较患者组与对照组DRD5基因各等位基因分布频率。结果　 ( 1)患者组与对照组之间等位基因分布的差异无显著性 ( χ2 =12 2 6 ,P >0 0 5 )。 ( 2 )女性患者比男性患者及对照组 14 0bp等位基因有更高的分布频率 ;与男性患者比较 ,相对危险度 (RR) =2 73( χ2 =5 33,P <0 0 5 ) ;与对照组比较 ,RR =2 0 1( χ2 =4 5 9,P <0 0 5 )。结论　未发现汉族人群中DRD5基因多态性与精神分裂症存在明显关联 ,但该基因多态性可能影响不同性别间的疾病易感性     

多巴胺转运体基因与迟发性运动障碍的关联性

目的：探讨多巴胺转运体(DAT1)基因小卫星多态与迟发性运动障碍(TD)的关联性。方法：采用Amp—FLP技术，对99例精神分裂症伴TD患者和120名正常人的DAT1基因多态性进行检测，比较各组间等位基因和基因型频率分布的差异。结果：共观察到5种等位基因：320bp、360bp、440bp、480bp和520bp。经吻合度检验，TD组和正常对照组DAT1基因各基因型的分布均符合Hardy-Weinberg平衡法则。与正常对照组相比较，TD组中仅360bp等位基因频率显著减少(P＜0．05)。经关联性分析，DAT1基因该多态与TD不相关联。在TD组中，基因型频数及等位基因频数与病程、家族史、药物、剂量和异常不自主运动评定量表(AIMS)评分无显著性意义(P＞0．05)：结论：DAT1基因该位点多态可能与TD的发生无关。     

Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

It has been suggested that dopamine D3 receptor (DRD3) may have important implications for antipsychotic-induced tardive dyskinesia (TD). Previous studies have demonstrated an association between a serine to glycine polymorphism in the first exon of the DRD3 gene and TD; however, the results have been inconsistent. Therefore, we have replicated these studies using a Chinese sample population. A total of 115 schizophrenic patients from chronic wards were assessed for TD severity using the Abnormal Involuntary Movements Scale (AIMS) and were subsequently genotyped for the DRD3 polymorphism. The mean AIMS score for patients carrying the heterozygote (DRD3(ser-gly)) was significantly greater than for those with the homozygotes (DRD3(ser-ser) and DRD3(gly-gly)). Our results are in line with a previous report, the results of which suggest that the presence of the DRD3(ser-gly) genotype may be a risk factor for the development of TD in patients treated with antipsychotics.     

Association between TNF-α promoter -308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia

Objective

Previous studies have indicated that the immune may be involved in the pathogenesis of tardive dyskinesia (TD). Some genetic polymorphisms in the human leukocyte antigen (HLA) I and II regions have been associated with TD, and the tumor necrosis factor-α (TNF-α) gene is located in the HLA III region. TNF-α levels in the striatum significantly increased in haloperidol-induced TD in rats. The TNF-α gene −308A/G single nucleotide polymorphism (SNP) has been shown to directly influence TNF-α expression. The genetic association between the TNF-α gene −308A/G SNP and TD is unclear. The present study investigated whether this variation is associated with clinical phenotypes and TD in schizophrenia in a genetically homogeneous northern Chinese Han population.

Methods

We genotyped the TNF-α gene −308A/G SNP in patients with schizophrenia with TD (n = 350) and without TD (n = 410). The Abnormal Involuntary Movement Scale (AIMS) and Positive and Negative Syndrome Scale (PANSS) were used to assess the severity of TD and psychopathology of schizophrenia, respectively.

Results

The allele and genotype frequencies did not significantly differ between patients with schizophrenia with and without TD (p > 0.05). No significant difference was found in the total AIMS score between the genotypes (p > 0.05). However, the PANSS negative symptom subscore was associated with risk for TD (p = 0.004), and a significant difference was found in total AIMS score between the genotypes in TD patients (p = 0.013).

Conclusion

The TNF-α gene −308A/G polymorphism does not appear to play a major role in the susceptibility to TD in patients with schizophrenia in a northern Chinese Han population. However this polymorphism may play a role in the TD severity.     

多巴胺D2受体基因多态性与脑出血的相关性研究

目的 探讨多巴胺D2受体（DRD2）基因TaqI位点多态性与中国湖南地区汉族人群脑出血发病的相关性.方法 本研究筛选121例脑出血患者,匹配103例正常体检人群为对照,PCR-RFLP检测DRD2 TaqI基因多态性.结果 DRD2 TaqI三种基因型（A1A1,A1 A2,A2A2）频率及两种等位基因（A1,A2）频率在脑出血组和正常对照组分布的差异无统计学意义（P＞0.05）.脑出血组中高血压亚组、非高血压亚组及对照组三者两两比较DRD2 TaqI基因型频率分布的差异无统计学意义（P＞0.05）.Logistic回归调整了脑出血环境因素的影响后,DRD2 TaqI基因多态性仍与脑出血的无相关性（P＞0.05）.结论 DRD2 TaqI基因多态性可能与中国湖南地区汉族人群脑出血无关.     

精神分裂症与5-羟色胺受体2A多态性相关性研究

目的 探测精神分裂症与5-HT2A受体基因多态性关系。方法用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）技术分析90例精神分裂症患者的5-HT2A受体（T102C）基因多态性,并以90例正常人作为对照。结果 在精神分裂症组和正常对照组中,等住基因A1、A2及基因型A1／A1、A1／A2、A2／A2的差异没有显著性（P〉0．05）。结论 本组样本中5-HT2A受体（T102C）基因多态性与精神分裂症无相关性。提示5-HT2A受体基因（T102C）突变可能不是导致精神分裂症发病的主要因素。     

Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia.

Dopamine receptor antagonism is a common mechanism underlying the therapeutic efficacy of all classical antipsychotic drugs. It is also thought to underlie the propensity of these agents to induce the movement disorder, tardive dyskinesia (TD), in one fifth of chronically exposed schizophrenia patients. We examined the polymorphic serine to glycine substitution in the first exon of the gene encoding the dopamine D3 receptor (DRD3) inn 53 schizophrenia patients with TD, 63 matched patients with similar antipsychotic exposure but no TD and 117 normal controls. There was a difference in allele frequency that was of borderline significance (P = 0.055), due to an excess of the DRD3gly allele (allele 2) in the schizophrenia patients with TD. The difference in genotype distribution among the groups was highly significant (chi2 = 19.1, d.f. 4, P = 0.0008) due to an excess of the DRD3ser-gly genotype in the schizophrenia patients with TD. The difference between the schizophrenia patients with TD and the controls was highly significant (chi2 = 19.0, d.f. 2, P = 0.00007), even after correction for multiple testing, as was the difference between the combined group of schizophrenia patients and the controls (chi2 = 12.2, d.f. 2, P = 0.002). Comparing the schizophrenia patients with and without TD, genotypes containing the gly allele (DRD3ser-gly and DRD3gly-gly genotypes combined) were significantly associated with dyskinesia (OR = 2.62, 95% CI 1.18-5.59, P = 0.02). DRD3 genotype and age at first antipsychotic treatment contributed significantly to total score on the Abnormal Involuntary Movements Scale (AIMS). The contribution of DRD3 to the variance in AIMS total was 5.2% and the total proportion of the variance accounted for by these two variables together was 11.9%. These results support and extend the report by Steen et al (1997) of an association between DRD3 and TD in schizophrenia patients.     

Possible interaction between MAOA and DRD2 genes associated with antisocial alcoholism among Han Chinese men in Taiwan

Both monoamine oxidase A (MAOA) and dopamine D(2) receptor (DRD2) genes have been considered as candidate genes for antisocial personality disorder with alcoholism (Antisocial ALC) [Parsian, A., 1999. Sequence analysis of exon 8 of MAO-A gene in alcoholics with antisocial personality and normal controls. Genomics. 45, 290-295.; Samochowiec, J., Lesch, K.P., Rottmann, M., Smolka, M., Syagailo, Y.V., Okladnova, O., Rommelspacher, H., Winterer, G., Schmidt, L.G., Sander, T., 1999. Association of a regulatory polymorphism in the promoter region of the monoamine oxidase A gene with antisocial alcoholism. Psychiatry. Res. 86, 67-72.; Schmidt, L.vG., Sander, T., Kuhn, S., Smolka, M., Rommelspacher, H., Samochowiec, J., Lesch, K.P., 2000. Different allele distribution of a regulatory MAO-A gene promotor polymorphism in antisocial and anxious-depressive alcoholics. J. Neural .Transm. 107, 681-689.]. However, the association between alcoholism and MAOA or DRD2 gene has not been universally accepted [Lee, J.F., Lu, R.B., Ko, H.C., Chang, F.M., Yin, S.J., Pakstis, A.J., Kidd, K.K., 1999. No association between DRD(2) locus and alcoholism after controlling the ADH and ALDH genotypes in Chinese Han population. Alcohol. Clin. Exp. Res. 23, 592-599.; Lu, R.B., Lin, W.W., Lee, J.F., Ko, H.C., Shih, J.C., 2003. Neither antisocial personality disorder nor antisocial alcoholism association with MAOA gene among Han Chinese males in Taiwan. Alcohol. Clin. Exp. Res. 27, 889-893.]. Since dopamine is metabolized to 3,4-dihydroxyphenyl-acetaldehyde (DOPAL) via monoamine oxidase (MAO) [Westerink, B.H., de Vries, J.B., 1985. On the origin of dopamine and its metabolite in predominantly noradrenergic innervated brain areas. Brain. Res. 330, 164-166.], the interaction between MAOA and DRD2 genes might be related to Antisocial ALC. The present study aimed to determine whether Antisocial ALC might be associated with the possible interactions of DRD2 gene with MAOA gene. Of the 231 Han Chinese subjects who were recruited for the study, 73 participants were diagnosed with Antisocial ALC and 158 subjects were diagnosed with antisocial personality disorder without alcoholism (Antisocial Non-ALC). The DRD2 TaqI A and MAOA-uVNTR (variable number of tandem repeat located upstream) polymorphisms were not found to be associated with Antisocial ALC. However, an association between DRD2 TaqI A polymorphisms and Antisocial ALC was shown only after stratification for the MAOA-uVNTR 4-repeat polymorphism. Additionally, after multiple logistic regressions, we found that, under stratification of MAOA-uVNTR 4-repeat polymorphism and in comparison with the DRD2 A1/A1 genotype as a reference group, the DRD2 A1/A2 genotype has a possible protective effect against alcoholism in individuals with antisocial personality disorder (ASPD). We concluded that the possible interactions between MAOA-uVNTR polymorphism and DRD2 TaqI A polymorphism might be related to Antisocial ALC among Han Chinese men in Taiwan.     

精神分裂症和亚甲基四氢叶酸还原酶基因的核心家系研究

目的探讨亚甲基四氢叶酸还原酶(MTHFR)基因与中国西北地区汉族精神分裂症的关系。方法应用聚合酶链反应-限制性片段长度多态性方法(PCR-RFLP),检测106个精神分裂症核心家系MTHFR基因的C677T和A1298C多态性,采用单倍体相对风险(HRR)和传递不平衡检验(TDT)分析MTHFR基因与精神分裂症的关系。结果①患者组与父母组MTHFR基因C677T和A1298C多态性基因型频率分布差异无统计学意义(x2=0.369,P>0.05;x2=1.214,P>0.05)。②HRR分析显示C677T、A1298C两位点等位基因在病例组和父母对照组的频数分布差异无统计学意义(x2=0.236,P>0.05;x2=3.327,P>0.05)。③TDT检验未发现C677T和A1298C两位点在精神分裂症中存在传递不平衡(x2=0.243,P>0.05;x2=2.123,P>0.05)。结论未发现MTHFR基因C677T和A1298C多态性与精神分裂症存在关联。     

Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome

OBJECTIVE: The pathophysiology of neuroleptic malignant syndrome is mainly explained by a central hypodopaminergic state. The familial occurrence of neuroleptic malignant syndrome suggests the involvement of a genetic mechanism in the predisposition to the syndrome. Therefore, the authors examined the association between the TaqI A polymorphism of the dopamine D(2) receptor gene (DRD(2)), which alters DRD(2) density and function, and the development of neuroleptic malignant syndrome. METHOD: The subjects were 15 psychiatric patients who had developed neuroleptic malignant syndrome (12 patients with schizophrenia and three with major depression) and 138 patients with schizophrenia who had never developed neuroleptic malignant syndrome. The TaqI A genotypes, A1 and A2 alleles, were determined by the polymerase chain reaction method. RESULTS: The frequency of the A1 allele was significantly higher in the patients who had developed neuroleptic malignant syndrome (56.8%) than in the patients who had not (35.1%). The proportion of the A1 carrier was significantly higher in the patients with neuroleptic malignant syndrome (14 [93.3%] of 15 patients) than in those without the syndrome (79 [57.2%] of 138 patients). CONCLUSIONS: These findings suggest that the TaqI A DRD(2) polymorphism is associated with the predisposition to neuroleptic malignant syndrome.     

多巴胺D2、D3受体基因多态性与汉族人精神分裂症相关研究

目的探索多巴胺D2受体(Dopamine D2receptor,DRD2)基因第8外显子Taq I A位点多态和多巴胺D3受体(Dopamine D3receptor,DRD3)基因第5内含子Msp I位点多态与汉族人群精神分裂症是否关联及其在不同性别是否存有差异。方法使用聚合酶链反应-限制性片段长度多态性(Polymerase chain reaction-re-striction fragment length polymorphism,PCR-RFLP)及DNA测序技术,对317例精神分裂症患者及310名对照DRD2Taq I A基因多态性和DRD3Msp I位点基因多态性进行检测。结果患者组与对照组间DRD2 Taq I A位点等位基因分布差异显著(P<0.01)、两两基因型对比(A1/A2与A1/A1相比:P<0.05;A2/A2与A1/A1相比:P<0.01)及两基因型联合对比(A1/A2+A2/A2与A1/A1:P<0.01)组间差异也显著。性别分层研究DRD2Taq I A位点女性组间差异显著(P<0.01),男性组间差异无意义(P>0.05)。DRD3Msp I位点的基因型频率、等位基因分布及性别分层分析等所有数据均显示患者组与对照组之间差异无统计学意义(P>0.05)。风险因子趋势检验结果DRD2Taq I A位点等位基因A2:P<0.01;DRD3Msp I位点等位基因2:P>0.05。结论所得数据支持DRD2Taq I A位点等位基因A2可能为精神分裂发生的风险因子,特别对女性而言。数据分析不支持DRD3Msp I位点基因与精神分裂发生有关。此结果需更进一步研究证实。     

Association of the manganese superoxide dismutase gene Ala–9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients

Objective

Several recent studies that have investigated the genetic association between the manganese superoxide dismutase (MnSOD) gene Ala–9Val single-nucleotide polymorphism (SNP) and tardive dyskinesia (TD) have produced conflicting results. This study was to investigate whether this SNP was associated with clinical phenotypes and antipsychotic-induced tardive dyskinesia (TD) in schizophrenia in a genetically homogeneous Han Chinese inpatient population.

Methods

Genotyping was performed for the MnSOD gene Ala–9Val SNP in Chinese schizophrenia patients with (n = 176) and without TD (n = 346). The severity of TD was assessed using the abnormal involuntary movement scale (AIMS), and psychopathology using the Positive and Negative Syndrome Scale (PANSS).

Results

The frequencies of genotypes and alleles did not differ significantly between schizophrenic patients with and without TD (both p > 0.05). Also, there was no significant difference in the AIMS total score between the Val/Val and Ala allele carrier groups (p > 0.05). However, the PANSS negative symptom subscore was significantly higher in patients with Val/Val genotype (21.8 ± 7.3) than those with Ala alleles (20.1 ± 7.7) (t = 2.32, p = 0.03).

Conclusion

While the MnSOD gene Ala–9Val polymorphism did not play a major role in the susceptibility to TD in schizophrenic patients, it might be associated with negative symptoms of schizophrenia.